Form 8-K - Current report:
SEC Accession No. 0001213900-25-092471
Filing Date
2025-09-26
Accepted
2025-09-26 17:25:27
Documents
13
Period of Report
2025-09-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0259031-8k_estrella.htm   iXBRL 8-K 30733
  Complete submission text file 0001213900-25-092471.txt   243290

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE esla-20250922.xsd EX-101.SCH 3862
3 XBRL DEFINITION FILE esla-20250922_def.xml EX-101.DEF 26752
4 XBRL LABEL FILE esla-20250922_lab.xml EX-101.LAB 36957
5 XBRL PRESENTATION FILE esla-20250922_pre.xml EX-101.PRE 25376
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0259031-8k_estrella_htm.xml XML 6079
Mailing Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608 (510) 318-9098
Estrella Immunopharma, Inc. (Filer) CIK: 0001844417 (see all company filings)

EIN.: 861314502 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40608 | Film No.: 251351532
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)